EUVIMEDEUVIMED entdecken
Crossref

Development of a nano-targeting chimera for the degradation of membrane and cytoplasmic proteins

Peipei Jin, Zhaozheng Chen, Ju Zhang, Haowen Li, Pengfei Wei, Ziyu Wang, Qiyu Feng, Hongyang Wang, Da Han, Yanyan Miao

Acta Biomaterialia · 2025-03 · 195 · 509-521

DOI: 10.1016/j.actbio.2025.02.023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Biomaterialia, 2025-03. Verfasst von Peipei Jin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Cancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University …. Hauptthemen laut MEDLINE: Proteolysis, Aptamers, Nucleotide, Membrane Proteins, Cytoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Various targeted protein degradation (TPD) approaches have been developed to overcome the limitations of traditional drug in eliminating pathogenic proteins by exploiting either the proteasomal or lysosomal pathway. However, there is still a lack of design strategies for TPD that utilize two distinct pathways to achieve the degradation of membrane and cytoplasmic proteins. Here, we develop a Nano-Targeting Chimera (Nano-APTAC), which is engineered by covalently attaching the protein-targeting aptamer to graphene oxide (GO) via the amide linkage, to hijack the autophagy-lysosome and ubiquitin-proteasome systems for targeted degradation of membrane and cytoplasmic proteins respectively. In contrast, a mixture of GO and aptamers without covalent interaction has no effect on protein degradation. Furthermore, the in vivo experiments demonstrate the efficacy of Nano-APTACs in depleting targeted proteins and inhibiting tumor growth. The work provides a versatile programmability platform, employing two distinct degradation systems to facilitate personalized design for the degradation of proteins regardless of their localization on the membrane or cytoplasm, and offering potential therapeutic benefits. STATEMENT OF SIGNIFICANCE: GO and aptamers have been combined for various applications. However, the utilization of this combination in TPD remains unknown. In this study, we found that the Nano-APTAC platform, constructed by covalently linking GO-aptamer chimera (not a simple mixture), can utilize autophagy-lysosome system and ubiquitin-proteasome system to degrade membrane and cytoplasmic proteins, respectively. The types of aptamers significantly influence the intracellular behavior of the chimeras, resulting in distinct subcellular localization and guiding the chimera to select specific degradation systems for protein removal. The Nano-APTAC's mode of action extremely expands the range of targeted proteins, prevents overload in specific degradation systems caused by excessive usage, and provides an exceptional level of adaptability in meeting diverse treatment requirements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteolysisAptamers, NucleotideMembrane ProteinsCytoplasmHumansAnimalsGraphiteAutophagyProteasome Endopeptidase ComplexLysosomesMiceMice, NudeCell Line, Tumor

Stichwörter der Autor:innen

AptamerAutophagy-lysosomeCancer therapyGraphene oxide (GO)Targeted protein degradationUbiquitin-proteasome

Substanzen

graphene oxideGraphiteAptamers, NucleotideMembrane ProteinsProteasome Endopeptidase Complex

Autor:innen und Institutionen

  • Department of Clinical Laboratory, Cancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, China; Core…
  • Department of Clinical Laboratory, Cancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, China.
  • Institute of Molecular Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China; Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, 310022, China.
  • School of Pharmacy, Shandong Technology Innovation Center of Molecular Targeting and Intelligent Diagnosis and Treatment, Binzhou Medical University, Yantai, 264003, China.
  • Department of Clinical Laboratory, Cancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, China. Elect…
  • Department of Clinical Laboratory, Cancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230036, China; Natio…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Jin, P., Chen, Z., Zhang, J., Li, H., Wei, P., Wang, Z., Feng, Q., Wang, H., Han, D., & Miao, Y. (2025). Development of a nano-targeting chimera for the degradation of membrane and cytoplasmic proteins. Acta Biomaterialia, 195, 509-521. https://doi.org/10.1016/j.actbio.2025.02.023

Vancouver

Jin P, Chen Z, Zhang J, Li H, Wei P, Wang Z, et al. Development of a nano-targeting chimera for the degradation of membrane and cytoplasmic proteins. Acta Biomaterialia. 2025;195:509-521. doi:10.1016/j.actbio.2025.02.023

BibTeX
@article{Jin2025,
  author = {Jin, Peipei and Chen, Zhaozheng and Zhang, Ju and Li, Haowen and Wei, Pengfei and Wang, Ziyu and Feng, Qiyu and Wang, Hongyang and Han, Da and Miao, Yanyan},
  title = {Development of a nano-targeting chimera for the degradation of membrane and cytoplasmic proteins},
  journal = {Acta Biomaterialia},
  year = {2025},
  volume = {195},
  pages = {509--521},
  doi = {10.1016/j.actbio.2025.02.023}
}
Kostenlos starten →